Seeking transpaRINcy for rituximab dosing in NMOSD - Authors' reply

Affiliations

¹ Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto 616-8255, Japan. Electronic address: tahara.masayuki.ne@mail.hosp.go.jp.
² Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto 616-8255, Japan.

Comment

Masayuki Tahara et al. Lancet Neurol. 2020 Sep.

. 2020 Sep;19(9):716-717.

doi: 10.1016/S1474-4422(20)30281-7.

¹ Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto 616-8255, Japan. Electronic address: tahara.masayuki.ne@mail.hosp.go.jp.
² Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto 616-8255, Japan.

No abstract available

Comment on

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Tahara M, et al. Lancet Neurol. 2020 Apr;19(4):298-306. doi: 10.1016/S1474-4422(20)30066-1. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199095 Clinical Trial.